ACCURAY INCORPORATED SUNNYVALE, Calif., Jan. 28, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today financial results for the second fiscal quarter and six months ended December 31, 2015.
http://photos.prnewswire.com/prnvar/20160108/320376LOGO
Fiscal Second Quarter Highlights
-- Gross orders were $67.1 million; single and dual vault sites comprised
more than 50 percent of total TomoTherapy(®) System orders; replacement
orders to existing accounts comprised approximately 15 percent of all
system orders
-- Total revenue was $108.9 million, an increase of 11 percent
year-over-year or 15 percent on a constant currency basis
-- Gross profit margins expanded sequentially to 39.1 percent from 37.8
percent
-- Operating income was near breakeven compared to a loss of $3.6 million
in the prior year
-- Adjusted EBITDA was $6.8 million compared to $3.7 million in the prior
year
-- Cash, cash equivalents and investments increased $2.7 million compared
to a decrease of $1.9 million in the prior year
"In the second quarter we achieved an all time high revenue quarter and near breakeven operating income, demonstrating that we are continuing to execute on each of our strategic commercial initiatives. Based on our commercial momentum, we expect that order and revenue growth in the second half of the fiscal year will be at levels well above overall market growth," said Joshua H. Levine, president and chief executive officer of Accuray. "Additionally, in January 2016 we took steps to improve our capital structure by closing on a $70 million senior secured loan and subsequently retiring $63.4 million of convertible notes which were to mature in August 2016. We believe this demonstrates confidence on the part of the financial community in our ability to execute our commercial strategies and drive positive EBITDA. With the retirement of the notes and our intent to pay the remaining convertible notes in cash we have reduced potential dilution by 10.6 million shares of our common stock."
Financial Highlights
Gross product orders totaled $67.1 million for the second fiscal quarter. Ending product backlog was $366.7 million.
Total revenue was $108.9 million, an increase of 11 percent from the prior fiscal year second quarter and an increase of 15 percent on a constant currency basis. The Americas region total revenue was $51.0 million and total revenue outside of the Americas region was $57.9 million. Product revenue increased 17 percent to $55.8 million while service revenue increased 5 percent to $53.1 million.
Total gross profit was $42.6 million or 39 percent of sales, comprised of product gross margin of 41 percent and service gross margin of 37 percent. This compares to total gross margin of 39 percent, product gross margin of 43 percent and service gross margin of 36 percent for the prior fiscal year second quarter. On a constant currency basis, total gross margin for the second quarter of fiscal 2016 was 41 percent.
Operating expenses were $42.7 million, an increase of 1 percent compared with $42.1 million in the prior fiscal second quarter. The increase was primarily due to higher legal expenses, related to the amended award of $2.1 million for damages to the Company's former China distributor as well as increased research and development expenses to support ongoing product development efforts. These increases were partially offset by reduced compensation related expenses in sales and marketing and general and administrative functions.
In November 2015 Accuray's former distributor in China was awarded an interim award for damages of approximately $3.4 million. In January 2016, the International Chamber of Commerce International Court of Arbitration revised the award based on a clerical error they believe occurred in their calculation of the maximum amount of damages. Accuray incurred an additional $2.1 million in expenses related to this amended award in the second quarter of fiscal 2016. The remaining issue to be finalized in the arbitration relates to the payment of attorneys' fees.
Net loss improved to $6.0 million, or $0.08 per share, for the second quarter of fiscal 2016, compared to a net loss of $10.0 million, or $0.13 per share, for the second quarter of fiscal 2015.
Adjusted EBITDA for the second quarter of fiscal 2016 was $6.8 million, compared to $3.7 million in the second quarter of the prior fiscal year.
Cash, cash equivalents and investments were $155.8 million as of December 31, 2015, an increase of $2.7 million from September 30, 2015.
Six Month Highlights
For the six months ended December 31, 2015, total revenue reached $198.5 million, representing an increase of 10 percent or 14 percent on a constant currency basis, from the comparable period of fiscal year 2015. Product revenue for the six month period was $95.8 million, representing an increase of 19 percent while service revenue was $102.8 million, representing 3% growth over the comparable prior fiscal year period.
Gross profit margin for the six months ended December 31, 2015 was 39 percent, comprised of product gross margin of 42 percent and service gross margin of 35 percent. This compares to total gross margin of 37 percent for the comparable prior fiscal year period.
Operating expenses were $83.8 million for the six months ended December 31, 2015, compared with $85.2 million in the comparable prior fiscal year period.
Net loss for the six months ended December 31, 2015 was $19.1 million, or $0.24 per share, compared to a net loss of $31.6 million, or $0.41 per share, for the comparable prior fiscal year period.
Adjusted EBITDA for the six months ended December 31, 2015 was a positive $5.7 million, compared to a loss of $4.8 million in the comparable prior fiscal year period.
Cash, cash equivalents, and investments increased $11.9 million from June 30, 2015.
2016 Financial Guidance
Accuray reaffirmed previously provided financial guidance for fiscal 2016. Total revenue is expected to be between $395 million to $410 million and adjusted EBITDA is expected to range between $25 million to $35 million. Accuray continues to expect that gross orders for the fiscal year will be approximately $295 million, which would represent a 10 percent increase year over year.
This financial guidance is unchanged from that provided on January 11, 2016.
Conference Call Information
Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss these results. Conference call dial-in information is as follows:
-- U.S. callers: (855) 867-4103
-- International callers: (262) 912-4764
-- Conference ID Number (U.S. and international): 19257397
Individuals interested in listening to the live conference call via the Internet may do so by logging on to Accuray's website, www.accuray.com. In addition, a dial-up replay of the conference call will be available beginning January 28, 2016 at 5:00 p.m. PT/8:00 p.m. ET and ending February 4, 2016. The replay telephone number is (855) 859-2056 (USA) or (404) 537-3406 (International), Conference ID: 19257397.
Use of Non-GAAP Financial Measures
Accuray has supplemented its GAAP net loss with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation ("adjusted EBITDA"). Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a more meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net loss (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedule below.
Accuray presents certain measures, such as period-over-period revenue growth, on a constant currency basis, which excludes the effects of foreign currency translation. Due to the continuing strengthening of the U.S. dollar against foreign currencies and the overall variability of foreign exchange rates from period to period, management uses these measures on a constant currency basis to evaluate period-over-period operating performance. Measures presented on a constant currency basis are calculated by translating current period results at prior period monthly average exchange rates.
There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations, including management's expectations regarding growth in orders, gross profit margins, revenues and adjusted EBITDA, ability to meet financial targets, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to: the company's ability to convert backlog to revenue; the success of the adoption of our CyberKnife and TomoTherapy Systems; the company's ability to manage its expenses; continuing uncertainty in the global economic environment; and other risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, which was filed on August 28, 2015, the company's report on Form 10-Q, which was filed on November 5, 2015 and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Financial Tables to Follow
Accuray Incorporated
Consolidated Statements of Operations
(in thousands, except per share data)
(Unaudited)
Three Months Ended December
31, Six Months Ended December 31,
--------------------------- -----------------------------
2015 2014 2015 2014
---- ---- ---- ----
Gross Orders $67,078 $72,261 $132,006 $131,024
Net Orders 42,679 41,474 87,478 73,756
Order Backlog 366,668 357,831 366,668 357,831
Net revenue:
Products $55,759 $47,650 $95,754 $80,665
Services 53,153 50,505 102,789 99,871
Total net revenue 108,912 98,155 198,543 180,536
Cost of revenue:
Cost of products 32,717 27,171 55,734 47,836
Cost of services 33,624 32,495 66,340 66,410
Total cost of revenue 66,341 59,666 122,074 114,246
------ ------ ------- -------
Gross profit 42,571 38,489 76,469 66,290
Operating expenses:
Research and
development 14,931 13,917 29,227 28,066
Selling and marketing 15,076 15,802 28,493 33,776
General and
administrative 12,688 12,361 26,104 23,311
Total operating
expenses 42,695 42,080 83,824 85,153
------ ------ ------ ------
Loss from operations (124) (3,591) (7,355) (18,863)
Other expense, net (5,070) (5,528) (10,161) (10,989)
Loss before provision
for income taxes (5,194) (9,119) (17,516) (29,852)
Provision for income
taxes 833 873 1,537 1,790
Net loss $(6,027) $(9,992) $(19,053) $(31,642)
======= ======= ======== ========
Net loss per share -
basic and diluted $(0.08) $(0.13) $(0.24) $(0.41)
====== ====== ====== ======
Weighted average common shares used in computing
loss per share:
Basic and diluted 80,346 77,924 80,053 77,607
====== ====== ====== ======
Accuray Incorporated
Consolidated Balance Sheets
(in thousands)
(Unaudited)
December 31, June 30,
2015 2015
---- ----
Assets
Current assets:
Cash and cash
equivalents $88,451 $79,551
Investments 67,304 64,306
Restricted cash 2,596 3,734
Accounts receivable,
net 66,044 77,727
Inventories 111,513 106,151
Prepaid expenses and
other current assets 13,598 15,991
Deferred cost of
revenue 8,834 6,869
Total current assets 358,340 354,329
Property and equipment,
net 29,550 31,829
Goodwill 57,892 58,054
Intangible assets, net 11,587 15,564
Deferred cost of
revenue 2,152 1,500
Other assets 13,804 8,695
Total assets $473,325 $469,971
======== ========
Liabilities and equity
Current liabilities:
Accounts payable $19,561 $13,096
Accrued compensation 20,484 21,934
Other accrued
liabilities 23,839 18,720
Short-term debt 96,551 -
Customer advances 19,377 19,385
Deferred revenue 94,386 96,780
Total current
liabilities 274,198 169,915
Long-term liabilities:
Long-term other
liabilities 10,829 10,934
Deferred revenue 17,257 10,489
Long-term debt 110,172 202,853
Total liabilities 412,456 394,191
Commitment and contingencies
Equity:
Common stock 81 79
Additional paid-in
capital 476,387 471,430
Accumulated other
comprehensive loss (1,243) (426)
Accumulated deficit (414,356) (395,303)
Total equity 60,869 75,780
------ ------
Total liabilities and
equity $473,325 $469,971
======== ========
Accuray Incorporated
Reconciliation of GAAP Net Loss to Adjusted Earnings Before Interest, Taxes, Depreciation,
Amortization and Stock-Based Compensation (Adjusted EBITDA)
(in thousands)
(Unaudited)
Three Months Ended Six Months Ended December
December 31, 31,
------------------- ---------------------------
2015 2014 2015 2014
---- ---- ---- ----
GAAP net loss $(6,027) $(9,992) $(19,053) $(31,642)
Amortization of
intangibles (a) 1,988 1,988 3,976 3,976
Depreciation (b) 2,514 2,994 5,085 5,984
Stock-based
compensation (c) 3,365 3,854 5,879 7,127
Interest expense, net
(d) 4,138 4,023 8,294 8,011
Provision for income
taxes 833 873 1,537 1,790
Adjusted EBITDA $6,811 $3,740 $5,718 $(4,754)
====== ====== ====== =======
(a) consists of amortization of
intangibles -developed technology.
(b) consists of depreciation, primarily
on property and equipment.
(c) consists of stock-based
compensation in accordance with ASC
718.
(d) consists primarily of interest
income from available-for-sale
securities and interest expense
associated with our convertible
notes.
Accuray Incorporated
Forward-Looking Guidance
Reconciliation of Projected Net Loss to Projected Adjusted Earnings Before Interest,
Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA)
(in thousands)
(Unaudited)
Twelve Months Ending June
30, 2016
--------------------------
From To
---- ---
GAAP net loss $(28,200) $(18,300)
Amortization of
intangibles (a) 7,950 7,950
Depreciation (b) 10,850 10,850
Stock-based
compensation (c) 14,100 14,100
Interest expense, net
(d) 17,300 17,300
Provision for income
taxes 3,000 3,100
Adjusted EBITDA $25,000 $35,000
======= =======
(a) consists of amortization of
intangibles -developed technology.
(b) consists of depreciation, primarily
on property and equipment.
(c) consists of stock-based
compensation in accordance with ASC
718.
(d) consists primarily of interest
income from available-for-sale
securities and interest expense
associated with our convertible
notes.
Logo - http://photos.prnewswire.com/prnh/20160108/320376LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/accuray-generates-1089-million-in-second-quarter-revenues-300211580.html
SOURCE Accuray Incorporated
